In adults with postacute sequelae of COVID-19, nirmatrelvir-ritonavir did not improve symptoms at 10 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 39348701.
- Also identified by DOI 10.7326/ANNALS-24-02172-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Geng LN, Bonilla H, Hedlin H, et al. <b>Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial.</b> JAMA Intern Med. 2024;184:1024-1034. 38848477.